Literature DB >> 29633312

Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis.

Giovanni Caocci1, Olga Mulas2, Mario Annunziata3, Luigiana Luciano4, Massimiliano Bonifacio5, Ester Maria Orlandi6, Patrizia Pregno7, Sara Galimberti8, Antonella Russo Rossi9, Elisabetta Abruzzese10, Alessandra Iurlo11, Bruno Martino12, Nicola Sgherza13, Gianni Binotto14, Fausto Castagnetti15, Antonella Gozzini16, Claudio Fozza17, Monica Bocchia18, Anna Sicuranza18, Fabio Stagno19, Fabio Efficace20, Emilio Usala2, Fiorenza De Gregorio4, Luigi Scaffidi5, Chiara Elena6, Francesca Pirillo7, Claudia Baratè8, Malgorzata Monika Trawinska10, Daniele Cattaneo11, Claudia Labate12, Gabriele Gugliotta15, Matteo Molica21, Giorgina Specchia9, Giorgio La Nasa1, Robin Foà21, Massimo Breccia21.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29633312     DOI： 10.1002/ajh.25102

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  11 in total

Review 1.  Early Management of CML.

Authors:  Naranie Shanmuganathan; Timothy P Hughes
Journal:  Curr Hematol Malig Rep       Date:  2019-12       Impact factor: 3.952

Review 2.  Recommendations for the management of cardiovascular risk in patients with chronic myeloid leukemia on tyrosine kinase inhibitors: risk assessment, stratification, treatment and monitoring.

Authors:  Fernanda Salles Seguro; Carolina Maria Pinto Domingues Carvalho Silva; Carla Maria Boquimpani de Moura; Monika Conchon; Laura Fogliatto; Vaneuza Araujo Moreira Funke; André Abdo; Ariane Vieira Scarlatelli Macedo; Marilia Harumi Higushi Dos Santos; José Francisco Kerr Saraiva
Journal:  Hematol Transfus Cell Ther       Date:  2020-07-01

3.  Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart.

Authors:  Giovanni Caocci; Olga Mulas; Elisabetta Abruzzese; Luigiana Luciano; Alessandra Iurlo; Immacolata Attolico; Fausto Castagnetti; Sara Galimberti; Nicola Sgherza; Massimiliano Bonifacio; Mario Annunziata; Antonella Gozzini; Ester Maria Orlandi; Fabio Stagno; Gianni Binotto; Patrizia Pregno; Claudio Fozza; Malgorzata Monika Trawinska; Fiorenza De Gregorio; Daniele Cattaneo; Francesco Albano; Gabriele Gugliotta; Claudia Baratè; Luigi Scaffidi; Chiara Elena; Francesca Pirillo; Emilia Scalzulli; Giorgio La Nasa; Robin Foà; Massimo Breccia
Journal:  Hematol Oncol       Date:  2019-04-17       Impact factor: 5.271

4.  Metabolomic Analysis of Patients with Chronic Myeloid Leukemia and Cardiovascular Adverse Events after Treatment with Tyrosine Kinase Inhibitors.

Authors:  Giovanni Caocci; Martino Deidda; Antonio Noto; Marianna Greco; Maria Pina Simula; Olga Mulas; Daniele Cocco; Claudia Fattuoni; Giuseppe Mercuro; Giorgio La Nasa; Christian Cadeddu Dessalvi
Journal:  J Clin Med       Date:  2020-04-20       Impact factor: 4.241

5.  The CoV-2 outbreak: how hematologists could help to fight Covid-19.

Authors:  Sara Galimberti; Chiara Baldini; Claudia Baratè; Federica Ricci; Serena Balducci; Susanna Grassi; Francesco Ferro; Gabriele Buda; Edoardo Benedetti; Rita Fazzi; Laura Baglietto; Ersilia Lucenteforte; Antonello Di Paolo; Mario Petrini
Journal:  Pharmacol Res       Date:  2020-05-06       Impact factor: 7.658

6.  Meta-Analysis of Gastrointestinal Adverse Events from Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia.

Authors:  Prahathishree Mohanavelu; Mira Mutnick; Nidhi Mehra; Brandon White; Sparsh Kudrimoti; Kaci Hernandez Kluesner; Xinyu Chen; Tim Nguyen; Elaina Horlander; Helena Thenot; Vamsi Kota; Cassie S Mitchell
Journal:  Cancers (Basel)       Date:  2021-04-01       Impact factor: 6.575

Review 7.  Nilotinib related acute myocardial infarction with nonobstructive coronary arteries: a case report and literature review.

Authors:  Weiwei Chen; Beibei Du; Kun Liu; Zhixi Yu; Xingtong Wang; Ping Yang
Journal:  BMC Cardiovasc Disord       Date:  2022-02-13       Impact factor: 2.298

8.  Pro-Inflammatory and Pro-Oxidative Changes During Nilotinib Treatment in CML Patients: Results of a Prospective Multicenter Front-Line TKIs Study (KIARO Study).

Authors:  Anna Sicuranza; Ilaria Ferrigno; Elisabetta Abruzzese; Alessandra Iurlo; Sara Galimberti; Antonella Gozzini; Luigiana Luciano; Fabio Stagno; Antonella Russo Rossi; Nicola Sgherza; Daniele Cattaneo; Corrado Zuanelli Brambilla; Cristina Marzano; Carmen Fava; Olga Mulas; Emanuele Cencini; Adele Santoni; Vincenzo Sammartano; Alessandro Gozzetti; Luca Puccetti; Monica Bocchia
Journal:  Front Oncol       Date:  2022-02-01       Impact factor: 6.244

9.  Kill Two Birds with One Stone: A Multifunctional Dual-Targeting Protein Drug to Overcome Imatinib Resistance in Philadelphia Chromosome-Positive Leukemia.

Authors:  Bohan Ma; Hui Feng; Chao Feng; Yi Liu; Hailing Zhang; Jincheng Wang; Wenjuan Wang; Pengcheng He; Fan Niu
Journal:  Adv Sci (Weinh)       Date:  2022-03-03       Impact factor: 17.521

10.  Arterial hypertension assessment in a population with chronic myeloid leukemia.

Authors:  Ricardo Roa-Chamorro; Fernando Jaén-Águila; José Manuel Puerta-Puerta; Lucía Torres-Quintero; Pablo González-Bustos; Juan Diego Mediavilla-García
Journal:  Sci Rep       Date:  2021-07-19       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.